RE: Late reported trade15 Mar 2018 22:10
Half that!!! You're pulling my leg, aren't you Bob?
"Strong demand for our technology across the global territories".
"CE marked release of TexRAD Lung".
"Distribution partners in key territories and ongoing discussions with global players".
"Three pilot TexRAD Lung installations secured with existing research customers".
1.7 million people die from lung cancer each year. TexRAD Lung offers a major step forward in the early detection of the disease. Once TexRAD Lung is available for purchase and use by clinicians (starting in Asia and the UK I suspect) do you really think the market cap will be just �15 million (246.42mil shares x 6p)?
I know I don't. If a widely distributed clinical version of TexRAD Lung is only worth a �15 million mcap then I'd be astounded.
And why wouldn't you hold on to the shares in anticipation of inroads it will subsequently make in the US and European markets?
Then there's many other cancers that will benefit from TexRAD as the company progresses. Surely, you'd be tempted to hold on for those, wouldn't you?
My end of year guestimate is just the beginning of what this company can achieve. I'm looking for far more than that in future years.
On the other hand, I did post a smiley face at the end of my previous post if only to suggest that I cannot predict what will happen in any given timescale. After all, I never saw coming the Armageddon that TB has caused in the last 9 months.